Key result
Reduced-dose prasugrel monotherapy without aspirin undergoes feasibility and safety testing post-PCI in the ASET Japan pilot.
Why the study?
The study was designed to evaluate the feasibility and safety of reduced-dose prasugrel monotherapy without aspirin after PCI with a SYNERGY stent in East Asian patients with CCS or NSTE-ACS.
Does reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent prevent ischemic and bleeding events in Japanese patients with CCS or NSTE-ACS?
Does reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent prevent ischemic and bleeding events in Japanese patients with CCS or NSTE-ACS?
The ASET Japan pilot study is designed to evaluate the feasibility and safety of an aspirin-free, reduced-dose prasugrel monotherapy strategy after PCI with the SYNERGY stent in East Asian patients.
Answers are grounded in this paper and cite their sources.
Tests aspirin-free prasugrel monotherapy post-PCI in Japanese patients; leaves open whether it safely reduces events versus standard regimens.
The Acetyl Salicylic Elimination Trial (ASET) Japan pilot study is a multicentre, single-arm, open-label, proof-of-concept study with a stopping rule based on the occurrence of definite stent thrombosis. This study aims to demonstrate the feasibility and safety of low-dose prasugrel monotherapy following percutaneous coronary intervention (PCI) in Japanese patients presenting with chronic coronary syndromes (CCS) or non-ST-elevation acute coronary syndromes (NSTE-ACS). Four hundred patients with a SYNTAX score <23 requiring PCI due to CCS or NSTE-ACS will be screened and considered eligible for the study. The enrolment is planned in two phases: 1) 200 patients presenting with CCS, followed by 2) 200 patients presenting with NSTE-ACS. After optimal PCI with implantation of a SYNERGY (Boston Scientific) stent, patients will be enrolled and loaded with prasugrel 20 mg, followed by a maintenance dose of prasugrel 3.75 mg once daily without aspirin continued for 3 months in Phase 1 (CCS patients), and for 12 months in Phase 2 (NSTE-ACS patients). After these follow-up periods, prasugrel will be replaced by standard antiplatelet therapy according to local practice. The primary endpoint is a composite of cardiac death, target vessel myocardial infarction, or definite stent thrombosis after the index procedure. The primary bleeding endpoint is any Bleeding Academic Research Consortium type 3 or 5 bleeding occurring within 3 months of the index PCI for CCS patients, or 12 months for NSTE-ACS patients. The ASET Japan study is designed to demonstrate the feasibility and safety of reduced-dose prasugrel monotherapy after PCI in East Asian patients with acute and chronic coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Masuda et al. (2023) studied Chronic coronary syndromes or non-ST-elevation acute coronary syndromes (n=400). Prasugrel monotherapy was evaluated on Composite of cardiac death, target vessel myocardial infarction (>48 hours post-PCI), or definite stent thrombosis. The ASET Japan pilot study is designed to evaluate the feasibility and safety of reduced-dose prasugrel monotherapy without aspirin following PCI in 400 Japanese patients with acute and chronic coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: